unknown
Stage
1
Investors
About
Vima Therapeutics develops novel oral therapies targeting muscarinic cholinergic receptors to treat movement disorders such as dystonia and Parkinson's disease, aiming to improve patients' control over their movement.
Explore Vima Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.